Merck Wins FDA Backing for First Hepatitis C Drug in Decade
This article is for subscribers only.
Merck & Co. won U.S. approval for the first hepatitis C drug in almost a decade after studies showed it cured more patients than existing treatments.
The Food and Drug Administration cleared boceprevir to treat people with chronic hepatitis C in combination with interferon-based therapy, the agency said today in a statement. The drug will be sold under the name Victrelis.